Gosset Molecular Classification
Peptide aggregation, Protein aggregation
Other Names
Aβ aggregation, Amyloid plaque formation, Abeta aggregation, Aβ oligomerization
Disease Roles
Amyloid Beta Peptide Aggregation Overview
Amyloid beta (Aβ) peptide aggregation refers to the process by which Aβ peptides self-associate into various aggregated forms, including oligomers, protofibrils, fibrils, and plaques. This process is a hallmark of Alzheimer's disease (AD), with the accumulation of Aβ aggregates, particularly in the form of amyloid plaques, contributing to neurotoxicity and cognitive decline. Small soluble oligomers are considered the most neurotoxic species. Inhibiting or modulating amyloid beta peptide aggregation is a major therapeutic strategy for AD.
Mechanism of Action
Inhibition of Aβ aggregation; promotion of Aβ clearance
Biological Functions
Protein misfolding
Self-assembly
Neurotoxicity
Plaque formation
Disease Associations
Alzheimer's disease
Cerebral amyloid angiopathy
Safety Considerations
- Potential for off-target effects
- Risk of ARIA (Amyloid-Related Imaging Abnormalities) with antibody-based therapies
- Need for early intervention before extensive plaque formation
Interacting Drugs
Small molecules that prevent oligomerization/fibrillization
Biologics that prevent oligomerization/fibrillization
Natural compounds that inhibit toxic aggregate formation
Associated Biomarkers
| Biomarker |
|---|
| Aβ levels in cerebrospinal fluid (CSF) |
| Aβ PET imaging |